Our collective results suggest that while lung endothelial D2R expression decreases as SCLC develops acquired resistance to chemotherapy, administration of the D2R agonist cabergoline results in increased expression of D2R, suggesting that low D2R expression in chemotherapy-refractory SCLC will not necessarily render D2R agonist treatment ineffective. The gene discussed is DRD2; the disease is small cell lung carcinoma.